{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:39:19Z","timestamp":1794429559917,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41591-022-01868-2","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:35:56Z","timestamp":1655987756000},"page":"1599-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":643,"title":["Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma"],"prefix":"10.1038","volume":"28","author":[{"given":"Andrew X.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-8416","authenticated-orcid":false,"given":"Marina Ruiz","family":"de Galarreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Koeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O.","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Burgoyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-5189","authenticated-orcid":false,"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Verret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Chong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-1481","authenticated-orcid":false,"given":"Amaia","family":"Lujambio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9057-9786","authenticated-orcid":false,"given":"Yulei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1868_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee, M. S. et al. GO30140 Investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 21, 808\u2013820 (2020).","journal-title":"Lancet Oncol."},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR4","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749\u2013757 (2018).","journal-title":"Nat. Med."},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"598877","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack, S. P., Zhu, A. X. & Wang, Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities. Front. Immunol. 11, 598877 (2020).","journal-title":"Front. Immunol."},{"key":"1868_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"1868_CR8","doi-asserted-by":"publisher","first-page":"617335","DOI":"10.3389\/fonc.2021.617335","volume":"11","author":"Y Lei","year":"2021","unstructured":"Lei, Y., Li, X., Huang, Q., Zheng, X. & Liu, M. Progress and challenges of predictive biomarkers for immune checkpoint blockade. Front. Oncol. 11, 617335 (2021).","journal-title":"Front. Oncol."},{"key":"1868_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/labinvest.2017.37","volume":"97","author":"W Zhang","year":"2017","unstructured":"Zhang, W. et al. Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. Lab. Invest. 97, 873\u2013885 (2017).","journal-title":"Lab. Invest."},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1158\/0008-5472.CAN-11-1704","volume":"71","author":"JL Li","year":"2011","unstructured":"Li, J. L. et al. DLL4-notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 71, 6073\u20136083 (2011).","journal-title":"Cancer Res."},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296 (2019).","journal-title":"Lancet Oncol."},{"key":"1868_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"1868_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415\u20132426 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2019.08.031","volume":"136","author":"YJ Kim","year":"2019","unstructured":"Kim, Y. J. et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer 136, 122\u2013128 (2019).","journal-title":"Lung Cancer"},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"RM de Galarreta","year":"2019","unstructured":"de Galarreta, R. M. et al. \u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 9, 1124\u20131141 (2019).","journal-title":"Cancer Discov."},{"key":"1868_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1868_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1868_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s12276-020-00486-7","volume":"52","author":"HG Lee","year":"2020","unstructured":"Lee, H. G., Cho, M. Z. & Choi, J. M. Bystander CD4+ T cells: crossroads between innate and adaptive immunity. Exp. Mol. Med. 52, 1255\u20131263 (2020).","journal-title":"Exp. Mol. Med."},{"key":"1868_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker, V. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 711\u2013718 (2019).","journal-title":"Lancet Oncol."},{"key":"1868_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"1868_CR25","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR26","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"1868_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","volume":"73","author":"B Sangro","year":"2020","unstructured":"Sangro, B. et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J. Hepatol. 73, 1460\u20131469 (2020).","journal-title":"J. Hepatol."},{"key":"1868_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41416-019-0466-x","volume":"120","author":"DJ Pinato","year":"2019","unstructured":"Pinato, D. J. et al. Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. Br. J. Cancer 120, 1033\u20131036 (2019).","journal-title":"Br. J. Cancer"},{"key":"1868_CR30","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00262-012-1277-6","volume":"61","author":"LS Peng","year":"2012","unstructured":"Peng, L. S. et al. Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer. Cancer Immunol. Immunother. 61, 2183\u20132192 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"1868_CR31","doi-asserted-by":"publisher","first-page":"e42274","DOI":"10.1371\/journal.pone.0042274","volume":"7","author":"HH Yoon","year":"2012","unstructured":"Yoon, H. H. et al. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS ONE 7, e42274 (2012).","journal-title":"PLoS ONE"},{"key":"1868_CR32","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-11-3216","volume":"18","author":"RJ deLeeuw","year":"2012","unstructured":"deLeeuw, R. J., Kost, S. E., Kakal, J. A. & Nelson, B. H. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin. Cancer Res. 18, 3022\u20133029 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"e130116","DOI":"10.1172\/jci.insight.130116","volume":"4","author":"SG Kalathil","year":"2019","unstructured":"Kalathil, S. G., Hutson, A., Barbi, J., Iyer, R. & Thanavala, Y. Augmentation of IFN-\u03b3+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 4, e130116 (2019).","journal-title":"JCI Insight"},{"key":"1868_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Herv\u00e1s-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1868_CR35","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-04-3232","volume":"65","author":"LA Ormandy","year":"2005","unstructured":"Ormandy, L. A. et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457\u20132464 (2005).","journal-title":"Cancer Res."},{"key":"1868_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","volume":"15","author":"S Shetty","year":"2018","unstructured":"Shetty, S., Lalor, P. F. & Adams, D. H. Liver sinusoidal endothelial cells\u2014gatekeepers of hepatic immunity. Nat. Rev. Gastroenterol. Hepatol. 15, 555\u2013567 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1868_CR37","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.4049\/jimmunol.1201937","volume":"190","author":"RM Dunham","year":"2013","unstructured":"Dunham, R. M. et al. Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J. Immunol. 190, 2009\u20132016 (2013).","journal-title":"J. Immunol."},{"key":"1868_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","volume":"183","author":"A Sharma","year":"2020","unstructured":"Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377\u2013394 (2020).","journal-title":"Cell"},{"key":"1868_CR39","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1868_CR40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33, 853\u2013861 (2018).","journal-title":"Cancer Cell"},{"key":"1868_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth, J. D. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, Phase IIa multiple basket study. J. Clin. Oncol. 36, 536\u2013542 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1868_CR42","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.18632\/oncotarget.26998","volume":"10","author":"C Ang","year":"2019","unstructured":"Ang, C. et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget 10, 4018\u20134025 (2019).","journal-title":"Oncotarget"},{"key":"1868_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/liv.14706","volume":"41","author":"CN Wong","year":"2021","unstructured":"Wong, C. N. et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 41, 192\u2013203 (2021).","journal-title":"Liver Int."},{"key":"1868_CR44","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1158\/1078-0432.CCR-11-2322","volume":"18","author":"A Lachenmayer","year":"2012","unstructured":"Lachenmayer, A. et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 18, 4997\u20135007 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1868_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.174","volume":"50","author":"BH Sohn","year":"2018","unstructured":"Sohn, B. H., Park, I. Y., Shin, J. H., Yim, S. Y. & Lee, J. S. Glutamine synthetase mediates sorafenib sensitivity in \u03b2-catenin-active hepatocellular carcinoma cells. Exp. Mol. Med. 50, e421 (2018).","journal-title":"Exp. Mol. Med."},{"key":"1868_CR46","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/2159-8290.CD-19-0696","volume":"9","author":"P Berraondo","year":"2019","unstructured":"Berraondo, P., Ochoa, M. C., Olivera, I. & Melero, I. Immune desertic landscapes in hepatocellular carcinoma shaped by \u03b2-catenin activation. Cancer Discov. 9, 1003\u20131005 (2019).","journal-title":"Cancer Discov."},{"key":"1868_CR47","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","volume":"25","author":"R Pinyol","year":"2019","unstructured":"Pinyol, R., Sia, D. & Llovet, J. M. Immune exclusion-Wnt\/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin. Cancer Res. 25, 2021\u20132023 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1868_CR48","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116\u20132126 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1868_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s40425-019-0780-0","volume":"7","author":"JA Trujillo","year":"2019","unstructured":"Trujillo, J. A. et al. Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma. J. Immunother. Cancer 7, 295 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1868_CR50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"1868_CR51","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme, M. et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73, 539\u2013549 (2013).","journal-title":"Cancer Res."},{"key":"1868_CR52","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52, 1475\u20131485 (2020).","journal-title":"Exp. Mol. Med."},{"key":"1868_CR53","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3390\/cancers13092137","volume":"13","author":"P Fessas","year":"2021","unstructured":"Fessas, P. et al. Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. Cancers 13, 2137 (2021).","journal-title":"Cancers"},{"key":"1868_CR54","unstructured":"Lawrence, M., Degenhardt, J. & Gentleman, R. Package VariantTools. Bioconductor https:\/\/www.bioconductor.org\/packages\/devel\/bioc\/manuals\/VariantTools\/man\/VariantTools.pdf (2022)."},{"key":"1868_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00251-011-0579-8","volume":"64","author":"E Karosiene","year":"2012","unstructured":"Karosiene, E., Lundegaard, C., Lund, O. & Nielsen, M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 64, 177\u2013186 (2012).","journal-title":"Immunogenetics"},{"key":"1868_CR56","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1868_CR57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12859-020-03910-x","volume":"21","author":"S Canzler","year":"2020","unstructured":"Canzler, S. & Hackerm\u00fcller, J. multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data. BMC Bioinformatics 21, 561 (2020).","journal-title":"BMC Bioinformatics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01868-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:05:15Z","timestamp":1660802715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01868-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01868-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"27 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.X.Z. received consulting fees from Bayer, Eisai, Eli Lilly, Exelixis, F. Hoffmann\u2013La Roche, Merck, Gilead, Sanofi Aventis and Sirtex. M.R.G. has received grant support from Genentech. A.R.A., Y.G., S.L., H.K., J.S., W.V. and Y.W. are employees of Genentech and hold stock or other ownership interests in F. Hoffmann\u2013La Roche. W.Z. is an employee of Roche Tissue Diagnostics and holds stock and other ownership interests in Roche. C.-H.H. received consulting fees from AstraZeneca, Eli Lilly and Roche, and received honoraria from Bristol-Meyers Squibb, Eisai, Merck Sharp & Dohme, Ono Pharmaceutical and Roche. A.R.H. has received research funding from Genentech and Merck, and has been on a speakers\u2019 bureau for Eisai, BMS and Exelixis. B.-Y.R. has nothing to declare. T.Y. has received honoraria and consulting fees from Bristol-Myers Squibb. A.O.K. has received honoraria from Bayer Health, Bristol-Myers Squibb, Eisai, Exelixis, Genentech\/Roche and Merck; has received consulting fees from Bayer Health, Bristol-Myers Squibb, Eisai, Exelixis, Genentech\/Roche and Merck; has received institutional research funding from Adaptimmune, Bayer\/Onyx, Bristol-Myers Squibb, Genentech, Hengrui Pharmaceutical and Merck; and travel, accommodation and other expenses support from Bayer\/Onyx, Bristol-Myers Squibb, Exelixis and Merck. A.M.B. has received consulting fees from Deciphera, Exelixis and Genentech. F.D. has received consulting fees from Genentech\/Roche, Array BioPharma, Exelixis, Eisai, QED Therapeutics and Signatera; has been on a speakers\u2019 bureau for Genentech\/Roche, Amgen, Eisai, Ipsen, Exelixis, Sirtex Medical, Deciphera, Natera and Servier; has received institutional research funding from Bristol-Myers Squibb, AstraZeneca, Merck, Genentech, Taiho Pharmaceutical, Exelixis and Ipsen; and has an immediate family member who is an employee of Roche Diagnostics. R.S.F. has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, F. Hoffmann\u2013La Roche\/Genentech, Lilly, Merck, Novartis and Pfizer; has received institutional research funding from Bayer, Bristol-Myers Squibb, Eisai, Lilly, Merck, Novartis, Pfizer and F. Hoffmann\u2013La Roche\/Genentech; and has provided expert testimony for Novartis. H.C.T. has received honoraria from Roche, MSD Merck, Ipsen and AstraZeneca. A.L. has received consulting fees from AstraZeneca and research funding from Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}